Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Aytu Biopharma (AYTU) Capital Expenditures (2016 - 2025)

Aytu Biopharma has reported Capital Expenditures over the past 9 years, most recently at $17000.0 for Q4 2025.

Quarterly Capital Expenditures rose 183.33% to $17000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103000.0 through Dec 2025, down 78.13% year-over-year, with the annual reading at $228000.0 for FY2025, 30.7% down from the prior year.
Capital Expenditures was $17000.0 for Q4 2025 at Aytu Biopharma, roughly flat from $17000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $329000.0 in Q2 2024 and troughed at -$13.1 million in Q2 2021.
The 3-year median for Capital Expenditures is $17000.0 (2025), against an average of -$1.8 million.
Year-over-year, Capital Expenditures plummeted 123.21% in 2021 and then soared 183.33% in 2025.
A 3-year view of Capital Expenditures shows it stood at -$13.1 million in 2021, then surged by 100.05% to $6000.0 in 2024, then soared by 183.33% to $17000.0 in 2025.
Per Business Quant, the three most recent readings for AYTU's Capital Expenditures are $17000.0 (Q4 2025), $17000.0 (Q2 2025), and $69000.0 (Q1 2025).